Meeting
2021 ASCO Annual Meeting
Prevalence of HER2 low in breast cancer subtypes using the VENTANA anti-HER2/neu (4B5) assay.
Authors
Marietta Scott
AstraZeneca R&D, Cambridge, United Kingdom
Marietta Scott , Michel Erminio Vandenberghe , Paul Scorer , Anne-Marie Boothman , Craig Barker
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Discussion Session
Session Title
Breast Cancer—Metastatic
Track
Breast Cancer
Sub Track
HER2-Positive
Citation
J Clin Oncol 39, 2021 (suppl 15; abstr 1021)
DOI
10.1200/JCO.2021.39.15_suppl.1021
Abstract #
1021
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Annual Meeting
The proliferation biomarker SPAG5 expression in HER2 low and HER2 overexpression early breast cancer (BC) predicting tumour response to neoadjuvant chemotherapy (NACT) with and without trastuzumab.
First Author: Tarek Mohamed Ahmed Abdel-Fatah
Poster
2023 ASCO Annual Meeting
Whole-genome sequencing based assessment of HER2 focal amplification for precision oncology of breast cancers.
First Author: Ryul Kim
Poster
2023 ASCO Gastrointestinal Cancers Symposium
Computational pathology–based HER2 quantification to identify novel biomarkers in gastric cancer (GC).
First Author: Ansh Kapil
Poster
2017 Gastrointestinal Cancers Symposium
Loss of HER2 positivity after anti-HER2 chemotherapy in HER2-positive gastric cancer patients: Results of GASTric cancer HER2 reassessment study 3 (GASTHER3).
First Author: Seyoung Seo